Synta Pharmaceuticals Corporation

Madrigal Pharmaceuticals, Inc.

Berg LLC

Dinesh U Chimmanamada

Weiwen Ying

Shijie Zhang

Lijun Sun

David James

Junghyun Chae

Teresa Przewloka

Hao Li

Howard P Ng

Kevin Paul Foley

Zhenjian Du

Zachary Demko

Dan Zhou

Shuzhen Qin

Elena Kostik

Joseph A Burlison

Minghu Song

Chi-Wan Lee

Teresa Kowalczyk-Przewloka

Stefan M Schweizer

Keizo Koya

James G Barsoum

Shoujun Chen

Jun Jiang

Yu Xie

Christopher Borella

Mats Harald Holmqvist

Jerome Mahiou

Mitsunori Ono

Yumiko Wada

Junyi Zhang

Zhiqiang Xia

Kevin M Foley

Genliang Lu

Vivek Kannoth Vishnudas

David Proia

Santosh Ambadas Khedkar

Chih-Yi Yu

Neera Jain

Teresa Kowalczyk-Prezewloka

Teresa Kowalcyzk-Przewloka

Zhi Qiang Xia

Amit Kale

Sami Osman

Dharma Vutukuri

James Loch

Stefan Michael Schweizer

Shije Zhang

The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.

Combination therapies comprising targeted therapeutics

Targeted therapeutics

Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating conditions associated with modulation of UBE2K.

UBE2K modulators and methods for their use

The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a pharmaceutical composition comprising such a compound.

Triazole compounds that modulate HSP90 activity

The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.

Triazole compounds that modulate Hsp90 activity

The present invention relates to substituted pyrrole compounds of formula I and compositions comprising substituted tri-substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a tri-substituted' triazole compound of the invention, or a pharmaceutical composition comprising such a compound.

Triazole compounds that modualte HSP90 activity

Growing community of inventors

Arlington, MA, United States of America

Dinesh U Chimmanamada